Medincell SA - Asset Resilience Ratio

Latest as of September 2025: 45.63%

Medincell SA (MEDCL) has an Asset Resilience Ratio of 45.63% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€34.03 Million

≈ $39.78 Million USD Cash + Short-term Investments

Total Assets

€74.58 Million

≈ $87.19 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Medincell SA's Asset Resilience Ratio has changed over time. Check Medincell SA (MEDCL) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Medincell SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MEDCL market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€34.03 Million	45.63%
Total Liquid Assets	€34.03 Million	45.63%

Asset Resilience Insights

Very High Liquidity: Medincell SA maintains exceptional liquid asset reserves at 45.63% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Medincell SA Industry Peers by Asset Resilience Ratio

Compare Medincell SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for Medincell SA (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Medincell SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	59.48%	€53.80 Million ≈ $62.90 Million	€90.45 Million ≈ $105.75 Million	+47.49pp
2024-03-31	11.99%	€4.43 Million ≈ $5.18 Million	€36.95 Million ≈ $43.20 Million	+11.98pp
2023-03-31	0.01%	€3.00K ≈ $3.51K	€29.34 Million ≈ $34.30 Million	-15.72pp
2022-03-31	15.73%	€6.97 Million ≈ $8.15 Million	€44.30 Million ≈ $51.79 Million	+6.65pp
2021-03-31	9.08%	€5.78 Million ≈ $6.75 Million	€63.61 Million ≈ $74.36 Million	-6.81pp
2020-03-31	15.89%	€4.34 Million ≈ $5.07 Million	€27.31 Million ≈ $31.92 Million	-24.90pp
2019-03-31	40.80%	€15.49 Million ≈ $18.12 Million	€37.98 Million ≈ $44.40 Million	+40.66pp
2018-03-31	0.14%	€35.00K ≈ $40.92K	€25.35 Million ≈ $29.64 Million	-19.26pp
2017-03-31	19.40%	€4.51 Million ≈ $5.28 Million	€23.27 Million ≈ $27.20 Million	+2.62pp
2016-03-31	16.78%	€1.88 Million ≈ $2.19 Million	€11.17 Million ≈ $13.06 Million	--

pp = percentage points

About Medincell SA

PA:MEDCL France Biotechnology

Market Cap

$1.09 Billion

€931.42 Million EUR

Market Cap Rank

#9014 Global

#146 in France

Share Price

€25.94

Change (1 day)

-1.44%

52-Week Range

€15.70 - €38.46

All Time High

€38.46